ECE2019 Poster Presentations Diabetes, Obesity and Metabolism 2 (100 abstracts)
A novel oral pyruvate dehydrogenase kinase 4 inhibitor ameliorates various spectrum of metabolic diseases in mice
Jae-Han Jeon 1 , In-Kyu Lee 1 , Yeon-Kyung Choi 1 , Keun-Gyu Park 1 , Na-Young Kim 1 , Sung Don Park 1 , Jin Hee Ahn 2 & Min-Ji Kim 1
1Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; 2Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
Pyruvate dehydrogenase kinase 4 (PDK4) activation is associated with metabolic diseases including hyperglycemia, insulin resistance, allergies, and cancer. We report here a new series of allosteric PDK4 inhibitor modified from hit anthraquinone. A novel PDK4 inhibitor, namely compound 8c, improved glucose tolerance in diet-induced obese mice. PDH activity in muscle and liver was enhance d by compound 8c treatment. Given the importance of PDK4 in immune cells including mast cells, we studied the effect of compound 8c in a passive cutaneous anaphylaxis mouse model. Compound 8c successfully improved allergic reactions as evidenced by decreased Evans Blue extravasation in ears. Additionally, compound 8c exhibited anticancer activity by controlling cell proliferation, transformation, and apoptosis in colon cancer cell lines. PDK4 inhibitors could be widely applicable in a various spectrum of metabolic diseases including diabetes, allergies and obesity-related cancers.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more